ABSTRACT

Background: The relevance of parapneumonic effusion (DPN) and empyema lies in it’s morbidity and mortality and the upward trend. It has recently taken interest in exploring new biomarkers able to influence its outcome. Procalcitonin is a solid marker of systemic infection, however, few studies describe the role in DPN and empyema. The current study analyzed if procalcitonin has a role in the approach of unilateral pleural effusion such as parapneumonic pleural effusion and/or empyema. Material and methods: We designed a prospective observational clinical study involving patients admitted to our institution with unilateral pleural effusion for a period of 18 months. The contrast of the absolute value of serum PCT in 2 groups of study and the ability to discriminate infection such as parapneumonic pleural effusion and/or empyema was analyzed. Results: 49 patients divided into 2 groups (infectious vs. noninfectious) were included. At admission, the value of serum PCT was different between the two groups (1.42 ng/mL vs. 0.83 ng/mL). Regression analysis identified that serum PCT had adequate association with pleural infection. The PCT value that best discriminated this finding was ≥ 2 ng/mL, OR 4.1 (95% CI 1.1-15.3; p = 0.038). Conclusions: Procalcitonin is a useful serum biomarker in the diagnosis of pleural infection. However, more studies should be performed to reinforce our results.

KEYWORDS

Biomarkers, parapneumonic effusion, pneumonia, procalcitonin.

REFERENCES

1. Davies HE, Davies RJ, Davies CW; MBTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65 Suppl 2:ii41-53. doi: 10.1136/thx.2010.137000.

2. Burgos J, Falcó V, Pahissa A. The increasing incidence of empyema. Curr Opin Pulm Med 2013;19(4):350-356. doi: 10.1097/MCP.0b013e3283606ab5.

3. Porcel JM, Light RW. Parapneumonic pleural effusions and empyema in adults: current practice. Rev Clin Esp 2009;209(10):485-494.

4. Bhatnagar R, Maskell NA. Treatment of complicated pleural effusions in 2013. Clin Chest Med 2013;34(1):47-62. doi: 10.1016/j.ccm.2012.11.004.

5. Grijalva CG, Zhu Y, Nuorti JP, Griffin MR. Emergence of parapneumonic empyema in the USA. Thorax 2011;66(8):663-668. doi: 10.1136/thx.2010.156406.

6. Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: an increasing concern in Canada. Can Respir J 2008;15(2):85-89.

7. Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med 2006;174(7):817-823.

8. Ferreiro L, San José ME, Valdés L. Management of parapneumonic pleural effusion in adults. Arch Bronconeumol 2015;51(12):637-646. doi: 10.1016/j.arbres.2015.01.009.

9. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36(3):941-952. doi: 10.1097/CCM.0B013E318165BABB.

10. Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89(4):1512-1525.

11. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 2012;73(3):221-227. doi: 10.1016/j.diagmicrobio.2012.05.002.

12. Schuetz P, Christ-Crain M, Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med Wkly 2009;139(23-24):318-326. doi: smw-12584.

13. Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery 2009;146(1):72-81. doi: 10.1016/j.surg.2009.02.013.

14. Bezmarevic M, Mirkovic D, Soldatovic I, et al. Correlation between procalcitonin and intra-abdominal pressure and their role in prediction of the severity of acute pancreatitis. Pancreatology 2012;12(4):337-343. doi: 10.1016/j.pan.2012.05.007.

15. Maier M, Wutzler S, Lehnert M, et al. Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma 2009;66(1):243-249. doi: 10.1097/TA.0b013e31817c966f.

16. Suberviola B, Castellanos-Ortega A, Ballesteros MA, Zurbano F, Naranjo S, Miñambres E. Early identification of infectious complications in lung transplant recipients using procalcitonin. Transpl Infect Dis 2012;14(5):461-467. doi: 10.1111/j.1399-3062.2012.00780.x.

17. Sponholz C, Sakr Y, Reinhart K, Brunkhorst F. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006;10(5):R145.

18. Ko YC, Wu WP, Hsu CS, Dai MP, Ou CC, Kao CH. Serum and pleural fluid procalcitonin in predicting bacterial infection in patients with parapneumonic effusion. J Korean Med Sci 2009;24(3):398-402. doi: 10.3346/jkms.2009.24.3.398.

19. Doğan C, Bilaçeroğlu S, Çirak AK, Özsöz A, Özbek D. Diagnostic value of pleural fluid and serum procalcitonin levels in the diagnosis of parapneumonic pleural effusion. Tuberk Toraks 2013;61(2):103-109.

20. Lin MC, Chen YC, Wu JT, Ko YC, Wang CC. Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest 2009;136(1):205-211. doi: 10.1378/chest.08-1134.

21. Wang CY, Hsiao YC, Jerng JS, et al. Diagnostic value of procalcitonin in pleural effusions. Eur J Clin Microbiol Infect Dis 2011;30(3):313-318. doi: 10.1007/s10096-010-1082-0.

22. Zou MX, Zhou RR, Wu WJ, Zhang NJ, Liu WE, Fan XG. The use of pleural fluid procalcitonin and C-reactive protein in the diagnosis of parapneumonic pleural effusions: a systemic review and meta-analysis. Am J Emerg Med 2012;30(9):1907-1914. doi: 10.1016/j.ajem.2012.04.004.

23. Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014;34(4):263-273. doi: 10.3343/alm.2014.34.4.263.

24. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004;32(8):1715-1721.

25. Sasse SA, Jadus MR, Kukes GD. Pleural fluid transforming growth factor-beta 1 correlates with pleural fibrosis in experimental empyema. Am J Respir Crit Care Med 2003;168(6):700-705.

26. Guo SY, Zhou Y, Hu QF, Yao J, Wang H. Procalcitonin is a marker of gram-negative bacteremia in patients with sepsis. Am J Med Sci 2015;349(6):499-504. doi: 10.1097/MAJ.0000000000000477.

27. Meisner M, Tschaikowsky K, Palmaers T, Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 1999;3(1):45-50.

28. Porcel JM. Pleural fluid biomarkers: beyond the Light criteria. Clin Chest Med 2013;34(1):27-37. doi: 10.1016/j.ccm.2012.11.002.

29. Skouras V, Boultadakis E, Nikoulis D, et al. Prognostic value of C-reactive protein in parapneumonic effusions. Respirology 2012;17(2):308-314. doi: 10.1111/j.1440-1843.2011.02078.x.

30. Porcel JM, Bielsa S, Esquerda A, Ruiz-González A, Falguera M. Pleural fluid C-reactive protein contributes to the diagnosis and assessment of severity of parapneumonic effusions. Eur J Intern Med 2012;23(5):447-450. doi: 10.1016/j.ejim.2012.03.002.